

**ACRUX LIMITED
ABN 72 082 001 152
AND CONTROLLED ENTITIES**

**HALF-YEAR INFORMATION
FOR THE SIX MONTHS ENDED 31 DECEMBER 2010
PROVIDED TO THE ASX UNDER LISTING RULE 4.2A**

This half-year financial report is to be read in conjunction with the financial report for the year ended 30 June 2010.

Appendix 4D

Half Year Report for the six months to 31 December 2010

Name of entity

Acrux Limited

ABN or equivalent company reference: 72 082 001 152

1. Reporting period

Report for the half year ended 31 December 2010

Previous corresponding period

is the financial year ended 30 June 2010

and half year ended 31 December 2009

2. Results for announcement to the market

Revenues from ordinary activities (<i>item 2.1</i>)	Up	16,031%	to	\$'000 90,496
Profit from ordinary activities after tax attributable to members (<i>item 2.2</i>)	Up from	(2,128)	to	56,743
Net profit for the period attributable to members (<i>item 2.3</i>)	Up from	(2,128)	to	56,743
Brief explanation of any of the figures reported above necessary to enable the figures to be understood (<i>item 2.6</i>):				
Please see Review of Operations, in the Directors Report contained within the attached Financial Report for the half-year ended 31 December, 2010.				

3. Net tangible assets per security (*item 3*)

	December 31, 2010	December 31, 2009
Net tangible asset backing per ordinary security	77 cents	6 cents

4. The financial information provided in the Appendix 4D is based on the half year condensed financial report (attached), which has been prepared in accordance with Australian accounting standards.

5. Independent review of the financial report (*item 9*)

The financial report has been independently reviewed. The financial report is not subject to a qualified independent review statement.

**ACRUX LIMITED
ABN 72 082 001 152
AND CONTROLLED ENTITIES**

**FINANCIAL REPORT
FOR THE HALF-YEAR ENDED
31 DECEMBER 2010**

This half-year financial report is to be read in conjunction with the financial report for the year ended 30 June 2010.

**ACRUX LIMITED
ABN 725 082 001 152
AND CONTROLLED ENTITIES**

**FINANCIAL REPORT FOR THE HALF-YEAR ENDED
31 DECEMBER 2010**

TABLE OF CONTENTS

	Page
Directors' Report	3 - 5
Auditor's Independence Declaration	6
Financial Report for the half-year ended 31 December 2010	
Condensed Consolidated Statement of Comprehensive Income	7
Condensed Consolidated Statement of Financial Position	8
Condensed Consolidated Statement of Changes in Equity	9
Condensed Consolidated Statement of Cash Flows	10
Notes to the Financial Statements	11 - 17
Directors' Declaration	18
Independent Auditor's Review Report	19 - 20

ACRUX LIMITED
ABN 72 082 001 152
AND CONTROLLED ENTITIES

DIRECTORS' REPORT

The directors present their report together with the condensed financial report of the consolidated entity consisting of Acrux Limited and the entities it controlled, for the half-year ended 31 December 2010 and independent review report thereon. This financial report has been prepared in accordance with Australian Accounting Standards.

Directors Names

The names of the directors in office at any time during or since the end of the half-year are:

Name	Period of directorship
R Dobinson (Chairperson)	Director since 1998
H K Windle (Deputy Chairperson)	Director since 2001
B C Finnin	Director since 1999
R Treagus (Managing Director)	Director since 2007

The directors have been in office since the start of the financial period to the date of this report.

Review of Operations

On 23 November 2010 the US Food and Drug Administration (FDA) approved Axiron[®] for marketing in the United States. The approval resulted in milestone revenue of US\$87 million from licensee Eli Lilly under an exclusive global licence, manufacturing and distribution agreement.

The consolidated profit before tax for the half-year was \$81.6 million (2009: loss of \$2.1 million). The consolidated profit after tax was \$56.7 million (2009: loss of \$2.1 million) net of income tax expense of \$24.9 million.

Revenue

Total revenue for the half-year was \$90.5 million (2009: \$0.6 million). Revenue from licensees was \$88.7 million (2009: \$0.3 million), due to the receipt of US\$87 million from Eli Lilly. Interest on cash deposits increased to \$1.8 million (2009: \$0.2 million), due to higher cash reserves following the receipt of payments from Eli Lilly under the Axiron agreement.

ACRUX LIMITED
ABN 72 082 001 152
AND CONTROLLED ENTITIES

DIRECTORS' REPORT

Operating Expenses

Operating expenditure after capitalisation of product development expenditure was \$8.9 million (2009: \$2.7 million). Total expenditure before capitalisation was \$10.3 million (2009: \$5.6 million). The increased expenditure was due to royalties of \$3.0 million (2009: Nil) payable to Monash Investment Trust following the receipt of the US\$87 million milestone revenue from Eli Lilly and to foreign exchange losses of \$3.2 million (2009: Nil) incurred as the Australian dollar strengthened prior to settlement of the milestone revenue. These additional expenses were offset by a reduction in total external research and development expenses before capitalisation, which decreased to \$1.0 million (2009: \$2.3 million), as activities related to the development of Axiron wound down. Expenditure of \$1.4 million (2009: \$2.8 million) for Axiron and \$0.1 million (2009: \$0.1 million) for Ellavie[™] were capitalised as an asset, as required by AASB138 Intangible Assets. Details of capitalised expenditure are provided in note 2 of the notes to the financial statements.

The consolidated entity recognised an income tax expense of \$24.9 million for the 6 months to December 2010 (2009: Nil), of which approximately \$5 million was deferred tax expense. Current tax payable at 31 December 2010 was \$19.9 million.

Cash flow

Net cash inflow for the half-year was \$88.6 million (2009: \$5.0 million outflow), resulting in cash and cash equivalents at 31 December 2010 of \$147.1 million (30 June 2010: \$58.6 million). Receipts from licensees and government increased to \$86.0 million (2009: \$0.9 million) due to the receipt of the Axiron milestone revenue from Eli Lilly. Interest receipts increased to \$0.8 million (2009: \$0.2 million). Cash outflow associated with capitalised development expenses for Axiron and Ellavie reduced to \$1.4 million (2009: \$3.3 million). Cash received on exercise of employee share options increased to \$7.4 million (2009:\$1.2 million).

Contributed Equity

The exercise of employee share options during the half-year added \$7.4 million (2009: \$1.2 million) to Contributed Equity.

The number of outstanding employee share options on issue at the end of the reporting period was 0.6 million (2009: 6.1 million), representing 0.3% of the issued share capital. These options have exercise prices between 51 cents and \$1.84 per share.

**ACRUX LIMITED
ABN 72 082 001 152
AND CONTROLLED ENTITIES**

DIRECTORS' REPORT

Auditor's Independence Declaration

A copy of the auditor's independence declaration, as required under section 307C of the *Corporations Act 2001*, in relation to the review for the half-year is provided with this report.

Rounding of amounts to nearest thousand dollars

The amounts contained in the report and in the financial report have been rounded to the nearest thousand dollars (where rounding is applicable) under the option available to the company under ASIC Class Order 98/0100. The company is an entity to which the Class Order applies.

Signed in accordance with a resolution of the directors:

A handwritten signature in black ink, appearing to read 'H K Windle', written in a cursive style.

H K Windle, Director

Dated this 23rd day of February, 2011

AUDITOR'S INDEPENDENCE DECLARATION
To the Directors of Acrux Limited

In relation to the half-year independent auditor's review for the six months to 31 December 2010, to the best of my knowledge and belief there have been:

- (i) No contraventions of the auditor independence requirements of the *Corporations Act 2001*.
- (ii) No contraventions of any applicable code of professional conduct.



PITCHER PARTNERS
Melbourne



S D Whitchurch
23 February 2011

ACRUX LIMITED
ABN 72 082 001 152
AND CONTROLLED ENTITIES

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE HALF-YEAR ENDED 31 DECEMBER 2010

	Notes	Half-Year 2010 \$'000	2009 \$'000
Revenue from licensees		88,660	334
Interest income		1,836	227
Total revenue		90,496	561
Employee benefits expense	2	(1,306)	(1,238)
Non-executive directors' fees		(124)	(118)
Share options expense		(13)	(102)
Depreciation and amortisation expenses		(133)	(240)
Occupancy and lease expenses		(175)	(176)
External research and development expenses	2	(342)	(374)
Foreign exchange losses		(3,200)	(9)
Professional fees		(158)	(263)
Royalty expenses		(2,999)	(12)
Other expenses	2	(420)	(153)
		(8,870)	(2,685)
Profit/(loss) before income tax expense		81,626	(2,124)
Income tax expense		(24,883)	(4)
Profit/(loss) from continuing operations		56,743	(2,128)
Total comprehensive income for the half-year		56,743	(2,128)
Total comprehensive income attributable to:			
Members of the parent		56,743	(2,128)
Non -controlling interest		-	-
		56,743	(2,128)
Basic earnings/(loss) per share (cents per share)		0.35	(0.01)
Diluted earnings/(loss) per share (cents per share)		0.34	(0.01)

The accompanying notes form part of these financial statements.

ACRUX LIMITED
ABN 72 082 001 152
AND CONTROLLED ENTITIES

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2010

	Notes	31 Dec 2010 \$'000	30 June 2010 \$'000
CURRENT ASSETS			
Cash and cash equivalents		147,094	58,609
Receivables		3,456	564
TOTAL CURRENT ASSETS		<u>150,550</u>	<u>59,173</u>
NON-CURRENT ASSETS			
Plant and equipment	3	169	1,024
Intangible assets	4	24,826	23,408
TOTAL NON-CURRENT ASSETS		<u>24,995</u>	<u>24,432</u>
TOTAL ASSETS		<u>175,545</u>	<u>83,605</u>
CURRENT LIABILITIES			
Current tax payable		19,924	-
Trade and other payables		4,564	1,670
Short-term provisions		327	305
TOTAL CURRENT LIABILITIES		<u>24,815</u>	<u>1,975</u>
NON-CURRENT LIABILITIES			
Deferred tax liabilities		6,050	1,094
Long-term provisions		71	67
TOTAL NON-CURRENT LIABILITIES		<u>6,121</u>	<u>1,161</u>
TOTAL LIABILITIES		<u>30,936</u>	<u>3,136</u>
NET ASSETS		<u><u>144,609</u></u>	<u><u>80,469</u></u>
EQUITY			
Contributed Equity	5	93,170	85,786
Reserves		2,074	2,061
Retained earnings		49,365	(7,378)
Parent entity interest		144,609	80,469
Non controlling interest		-	-
TOTAL EQUITY		<u>144,609</u>	<u>80,469</u>

The accompany notes form part of these financial statements.

ACRUX LIMITED
ABN 72 082 001 152
AND CONTROLLED ENTITIES

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE HALF-YEAR ENDED 31 DECEMBER 2010

	Notes	Contributed Equity \$'000	Reserves \$'000	Retained Earnings \$'000	Total Equity \$'000
Balance as at 1 July 2009		83,211	1,953	(53,941)	31,223
Loss for the period		-	-	(2,128)	(2,128)
Total comprehensive income for the half-year		-	-	(2,128)	(2,128)
Transactions with owners in their capacity as owners:					
Contributions		1,167	-	-	1,167
Employee Share Options Expense		-	102	-	102
Lapsed Employee Share Options		-	(9)	9	-
Total transactions with owners in their capacity as owners		1,167	93	9	1,269
Balance as at 31 December 2009		84,378	2,046	(56,060)	30,364
Balance as at 1 July 2010		85,786	2,061	(7,378)	80,469
Profit for the period		-	-	56,743	56,743
Total comprehensive income for the half-year		-	-	56,743	56,743
Transactions with owners in their capacity as owners:					
Contributions	5	7,384	-	-	7,384
Employee Share Options Expense		-	13	-	13
Lapsed Employee Share Options		-	-	-	-
Total transactions with owners in their capacity as owners		7,384	13	-	7,397
Balance as at 31 December 2010		93,170	2,074	49,365	144,609

The accompany notes form part of these financial statements.

ACRUX LIMITED
ABN 72 082 001 152
AND CONTROLLED ENTITIES

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
FOR THE HALF-YEAR ENDED 31 DECEMBER 2010

	Half-year	
	2010	2009
	\$'000	\$'000
CASH FLOW FROM OPERATING ACTIVITIES		
Receipts from licensees and government	85,985	854
Payments to suppliers and employees	(3,938)	(3,754)
Interest received	791	244
Withholding tax paid	(3)	(4)
Net cash provided by/(used in) in operating activities	82,835	(2,660)
CASH FLOW FROM INVESTING ACTIVITIES		
Payment for plant and equipment	(641)	(226)
Proceeds from the sale of plant and equipment	432	-
Payment for capitalised development costs	(1,405)	(3,323)
Net cash used in investing activities	(1,614)	(3,549)
CASH FLOW FROM FINANCING ACTIVITIES		
Net proceeds from issues of ordinary shares	7,397	1,167
Net cash provided by financing activities	7,397	1,167
Net increase/(decrease) in cash and cash equivalents	88,618	(5,042)
Foreign exchange differences on cash holdings	(133)	(86)
Cash and cash equivalents at beginning of half-year	58,609	14,736
Cash and cash equivalents at end of the half-year	147,094	9,608

The accompany notes form part of these financial statements.

ACRUX LIMITED
ABN 72 082 001 152
AND CONTROLLED ENTITIES

NOTES TO THE FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED
31 DECEMBER 2010

NOTE 1: BASIS OF PREPARATION OF THE HALF-YEAR FINANCIAL REPORT

This half-year financial report does not include all the notes of the type usually included in an annual financial report.

It is recommended that this half-year financial report be read in conjunction with the annual financial report for the year ended 30 June 2010 and any public announcements made by Acrux Limited during the half-year in accordance with any continuous disclosure obligations arising under the *Corporations Act 2001*.

The half-year financial report was authorised for issue by the directors as at the date of the directors' report.

(a) Basis of preparation of the half-year financial report

This general purpose half-year financial report has been prepared in accordance with Australian Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Act 2001*.

The half year financial report has been prepared under the historical cost convention, as modified by revaluations to fair value for certain classes of assets as described in the accounting policies.

(b) Summary of the significant accounting policies

The accounting policies applied in this half-year financial report are consistent with those of the annual financial report for the year ended 30 June 2010 and the corresponding half-year.

(i) Intangible Assets

The intangible assets accounting policy is significant to the preparation of the financial statements. Intangible assets are valued in the accounts at cost of acquisition. The balances are reviewed annually and any balances representing probable future benefits that are no longer anticipated are written off.

Intellectual Property

Purchased intellectual property is initially recorded at cost. Intellectual property with a finite life is carried at cost less any accumulated amortisation and any impairment losses. The intellectual property is amortised over the useful life of the relevant patents.

Research and Development

Expenditure during the research phase of a project is recognised as an expense when incurred. Product development costs are capitalised only when each of the following specific criteria has been satisfied:

1. Technical feasibility of completing development of the product and obtaining approval by regulatory authorities.
2. Ability to secure a commercial licensee for the product.
3. Availability of adequate technical, financial and other resources to complete development of the product, obtain regulatory approval and secure a commercial licensee.
4. Reliable measurement of expenditure attributable to the product during its development.
5. High probability of the product entering a major pharmaceutical market.

ACRUX LIMITED
ABN 72 082 001 152
AND CONTROLLED ENTITIES

NOTES TO THE FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED
31 DECEMBER 2010

NOTE 1: BASIS OF PREPARATION OF THE HALF-YEAR FINANCIAL REPORT
(continued)

(b) Summary of the significant accounting policies (continued)

(i) Intangible Assets (continued)

Capitalised development costs have a finite life and are amortised over the period from first commercial sale of the product to the date on which economic benefits to Acrux under a commercial licence agreement cease.

(c) Principles of Consolidation

The consolidated financial statements are those of the consolidated entity, comprising the financial statements of the parent entity and of all entities, which Acrux Limited controlled from time to time during the half-year and at balance date.

The financial statements of subsidiaries are prepared for the same reporting period as the parent entity, using consistent accounting policies. Adjustments are made to bring into line any dissimilar accounting policies, which may exist. All inter-company balances and transactions, including any unrealised profits or losses, have been eliminated on consolidation.

(d) Rounding Amounts

The company is of a kind referred to in ASIC Class Order CO 98/0100 and in accordance with that Class Order, amounts in the financial statements have been rounded off to the nearest thousand dollars, or in certain cases, to the nearest dollar.

ACRUX LIMITED
ABN 72 082 001 152
AND CONTROLLED ENTITIES

NOTES TO THE FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED
31 DECEMBER 2010

NOTE 2: RECONCILIATION OF OPERATING EXPENSES IMPACTED BY THE
CAPITALISATION OF DEVELOPMENT EXPENDITURE

	Half-year	
	31 Dec	31-Dec
	2010	2009
	\$'000	\$'000
Total employee benefits expense	1,873	1,960
Capitalised - Axiron [®]	(514)	(665)
Capitalised - Ellavie [™]	(53)	(57)
Per income statement	<u>1,306</u>	<u>1,238</u>
External research and development expenses	1,042	2,333
Capitalised - Axiron [®]	(663)	(1,916)
Capitalised - Ellavie [™]	(37)	(43)
Per income statement	<u>342</u>	<u>374</u>
Other expenses	618	406
Capitalised - Axiron [®]	(179)	(233)
Capitalised - Ellavie [™]	(19)	(20)
Per income statement	<u>420</u>	<u>153</u>
Total capitalised expenses		
Capitalised - Axiron [®]	1,356	2,814
Capitalised - Ellavie [™]	109	43
	<u>1,465</u>	<u>2,857</u>

ACRUX LIMITED
ABN 72 082 001 152
AND CONTROLLED ENTITIES

NOTES TO THE FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED
31 DECEMBER 2010

NOTE 3: PLANT AND EQUIPMENT

	Notes	31 Dec 2010 \$'000	30 June 2010 \$'000
Leasehold Improvements			
At cost		1,115	1,115
Accumulated amortisation		(1,115)	(1,115)
Total leasehold improvements	(a)	-	-
Plant and equipment			
At cost		550	1,561
Accumulated depreciation		(381)	(537)
Total plant and equipment	(a)	169	1,024
Total plant and equipment		169	1,024

(a) Reconciliations

Reconciliations of the carrying amounts of plant and equipment at the beginning and end of the period.

	31 Dec 2010 \$'000	30 June 2010 \$'000
<i>Leasehold improvements</i>		
Carrying amount at beginning	-	181
Additions	-	2
Amortisation expense	-	(183)
	-	-
<i>Plant and equipment</i>		
Carrying amount at beginning	1,024	1,591
Additions	683	715
Disposals	(1,452)	(1,085)
Depreciation expense	(86)	(197)
	169	1,024

ACRUX LIMITED
ABN 72 082 001 152
AND CONTROLLED ENTITIES

NOTES TO THE FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED
31 DECEMBER 2010

NOTE 4: INTANGIBLE ASSETS

	31 Dec	30 June
	2010	2010
	\$'000	\$'000
Intellectual Property		
At cost	1,200	1,200
Accumulated amortisation	(616)	(569)
Net carrying amount	<u>584</u>	<u>631</u>
Capitalised Development Expenses		
Ellavie™		
External research and development expenses	766	729
Employee benefits expense	169	116
Other capitalised expenses	136	117
	<u>1,071</u>	<u>962</u>
Axiron®		
External research and development expenses	17,415	16,752
Employee benefits expense	3,354	2,840
Other capitalised expenses	2,402	2,223
	<u>23,171</u>	<u>21,815</u>
Net carrying amount	<u>24,242</u>	<u>22,777</u>
Total Intangible Assets	<u><u>24,826</u></u>	<u><u>23,408</u></u>

AASB 138 'Intangible Assets' requires that development expenses are capitalised as an asset generating probable future economic benefits if a number of criteria are met. The Directors believe that these criteria have been met for Estradiol MDTs® (branded Evamist® in the USA and Ellavie™ outside the USA) and Axiron®. Acrux has the technical and financial capability to complete development of these two products, the expenditure can be reliably measured and the means of generating probable future revenue has been clearly demonstrated.

ACRUX LIMITED
ABN 72 082 001 152
AND CONTROLLED ENTITIES

NOTES TO THE FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED
31 DECEMBER 2010

NOTE 5: ISSUANCES OF EQUITY SECURITIES

	31 Dec	30 June	31 Dec	30 June
	2010	2010	2010	2010
Movements in shares on issue	No.	No.	\$'000	\$'000
Beginning of the financial year	160,556,216	159,400,216	85,786	83,211
Issued during the year:				
Employee share scheme	5,412,495	1,156,000	7,399	1,318
Less capital raising expenses			(15)	(7)
Tax credits on capital raising expenses			-	1,264
Net contributions from share issues			7,384	2,575
At reporting date	165,968,711	160,556,216	93,170	85,786

ACRUX LIMITED
ABN 72 082 001 152
AND CONTROLLED ENTITIES

NOTES TO THE FINANCIAL STATEMENTS FOR THE HALF-YEAR ENDED
31 DECEMBER 2010

NOTE 6: SEGMENT INFORMATION

The consolidated entity operates as a single operating segment. Internal management reporting systems present financial information as a single segment. The segment derives its revenue from developing and commercialising products using unique technology to administer drugs through the skin.

Additional information on revenue:	Half-year	
	31 Dec 2010 \$'000	31-Dec 2009 \$'000
Product/Service		
Axiron®	88,662	-
Other Revenue	1,834	561
Total revenue	<u>90,496</u>	<u>561</u>
Country of Origin		
Australia	1,836	227
Other:		
Switzerland	88,662	-
Overseas	(2)	334
	<u>90,496</u>	<u>561</u>
Additional information on non-current assets:	31 Dec 2010 \$'000	30 June 2010 \$'000
Australia		
Plant and Equipment	169	567
Intangible Assets	24,826	23,408
	<u>24,995</u>	<u>23,975</u>
Overseas		
Plant and Equipment	-	457
	<u>-</u>	<u>457</u>
Total non-current assets	<u>24,995</u>	<u>24,432</u>

Overseas Plant and Equipment represented purchased manufacturing equipment installed at the manufacturing facility of Orion Corporation in Finland.

NOTE 7: CONTINGENT LIABILITIES

There are no contingent liabilities as at 31 December 2010.

ACRUX LIMITED
ABN 72 082 001 152
AND CONTROLLED ENTITIES

DIRECTORS' DECLARATION

The directors declare that the financial statements and notes set out on pages 7 to 17 are in accordance with the *Corporations Act 2001* and:

- (a) Comply with Australian Accounting Standard AASB 134 "Interim Financial Reporting" and the *Corporations Regulations 2001*, and other mandatory professional requirements; and
- (b) Give a true and fair view of the financial position of the consolidated entity as at 31 December 2010 and of its performance for the half-year ended on that date.

In the directors' opinion there are reasonable grounds to believe that Acrux Limited will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the directors.



H K Windle
Director

Dated this 23rd day of February, 2011
Melbourne



**ACRUX LIMITED
ABN 72 082 001 152
AND CONTROLLED ENTITIES**

**INDEPENDENT AUDITOR'S REVIEW REPORT
TO THE MEMBERS OF
ACRUX LIMITED**

Report on the Half-Year Financial Report

We have reviewed the accompanying half-year financial report of Acrux Limited and controlled entities, which comprises the condensed consolidated statement of financial position as at 31 December 2010, the condensed consolidated statement of comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration of the consolidated entity comprising the company and the entities it controlled at the period's end or from time to time during the half year.

Directors' Responsibility for the Half-Year Financial Report

The directors of the Acrux Limited are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the consolidated entity's financial position as at 31 December 2010 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*. As the auditor of Acrux Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*.



PITCHER PARTNERS
An independent Victorian Partnership
ABN 27 975 255 196

**ACRUX LIMITED
ABN 72 082 001 152
AND CONTROLLED ENTITIES**

**INDEPENDENT AUDITOR'S REVIEW REPORT
TO THE MEMBERS OF
ACRUX LIMITED**

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Acrux Limited is not in accordance with the *Corporations Act 2001* including:

- (a) giving a true and fair view of the consolidated entity's financial position as at 31 December 2010 and of its performance for the half-year ended on that date; and
- (b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and *Corporations Regulations 2001*.

S D WHITCHURCH
Partner

PITCHER PARTNERS
Melbourne

23 February 2011